Anti-angiogenesis therapy for the treatment of ovarian cancer
A technology for ovarian cancer and therapy, applied in the direction of anti-growth factor immunoglobulin, antibody, anti-tumor drugs, etc., can solve the problem of high mortality rate of cases
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0306] Example 1: Carboplatin and Paclitaxel plus Placebo vs. Carboplatin and Paclitaxel plus Concurrent Bevacizumab, followed by Placebo, Versus Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab Anti, stage III in women with newly diagnosed, previously untreated, stage III (suboptimal and macroscopically optimal massively resected) or IV epithelial ovarian, primary peritoneal, or fallopian tube cancer test
[0307] Presents results from a phase III randomized study in patients with International Federation of Obstetrics and Gynecologic Oncology (FIGO) stages III and IV epithelial ovarian, primary peritoneal or fallopian tube cancer (epithelial ovarian, peritoneal primary or fallopian tube cancer). ) patients were evaluated for new treatment procedures. The primary objective included identifying the addition of five concurrent cycles of bevacizumab to six in women with newly diagnosed stage III (with any overall residual disease) and stage IV epithelial ovar...
Embodiment 2
[0361] Example 2. A randomized, two-arm, multicenter gynecologic cancer intergroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer
[0362] Results from a phase III randomized study (ICON7) to assess the safety and efficacy of adding bevacizumab to standard chemotherapy of carboplatin and paclitaxel are presented. The primary endpoint was determined in patients with newly diagnosed, histologically confirmed, high-risk International Federation of Gynecology and Obstetrics (FIGO) stages I and IIa (grade 3 or clear cell carcinoma only) and FIGO stages IIb-IV (all grades and All histologic types) epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, who have undergone primary surgery (mass excisional cytoreductive surgery or biopsy if the patient has FIGO stage IV disease) and will not be diagnosed before disease progression Whether the addition of bevacizumab to standard chemotherapy impr...
Embodiment 3
[0453] Example 3. A phase III, multicenter, randomized, blinded, placebo-controlled trial of carboplatin and gemcitabine plus bevacizumab in patients with platinum-sensitive recurrent ovarian, primary peritoneal, or fallopian tube cancer
[0454] Epithelial ovarian carcinoma (EOC) and its histologic and clinical equivalents, primary peritoneal carcinoma (PPC) and fallopian tube carcinoma, occur in the United States at an incidence of approximately 25,000 cases per year and are responsible for approximately 14,000 deaths per year. Because the disease tends to be asymptomatic in its early stages, most patients initially present with advanced (stage III or IV) disease. Although EOC, PPC, and fallopian tube cancers are sensitive to multiple chemotherapeutic agents, especially taxanes and platinum compounds, only 20%>-30%>patients with stage III or IV disease will be alive at 5 years. Patients with platinum-sensitive recurrent cancer (defined as disease recurrence more than 6 mont...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More